October 16, 2006 — The European Commission has approved pregabalin capsules for the treatment of central neuropathic pain associated with spinal cord injury, stroke, and multiple sclerosis; and ...

May 15, 2006 — Health Canada has approved a 500-mg tablet formulation of saquinavir mesylate that significantly reduces the daily pill count for patients with HIV; the European Commission has approved ...

Infliximab is a medication used to reduce the symptoms and signs of several chronic inflammatory disorders. It is approved for the treatment of Crohn’s disease, rheumatoid arthritis, psoriasis, ...

Inflectra (infliximab-dyyb)* and Remicade (infliximab) are brand-name prescription medications. They’re approved by the Food and Drug Administration (FDA) to treat similar autoimmune conditions. This ...

Infliximab is a monoclonal antibody that is administered intravenously to treat patients with chronic inflammatory diseases including Crohn’s disease, ulcerative colitis, rheumatoid arthritis, plaque ...

ATLANTA, Nov. 8, 2010 /PRNewswire/ -- Patients with active moderate to severe rheumatoid arthritis (RA) inadequately responding to either etanercept (Enbrel ®) or adalimumab (Humira ®) and who were ...

The European Medicines Agency (EMA) has backed the use of Celltrion Healthcare’s subcutaneous infliximab without initial intravenous loading doses. Securing the regulatory recommendation boosts ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved the subcutaneous formulation of Celltrion USA’s Zymfentra as maintenance therapy for patients ...

NEW YORK (Reuters) - Crohn's disease patients taking Johnson & Johnson's Remicade either alone or with azathioprine experienced steroid-free remission in significantly greater numbers than those ...

Merck & Co. today said it has launched in the U.S. a biosimilar of Remicade ® (infliximab), the blockbuster immune-mediated inflammatory disorders treatment it markets outside the U.S., including ...

TORONTO--(BUSINESS WIRE)--Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new brand name Remdantry TM ...